These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 14500372)

  • 1. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.
    Ruf W; Seftor EA; Petrovan RJ; Weiss RM; Gruman LM; Margaryan NV; Seftor RE; Miyagi Y; Hendrix MJ
    Cancer Res; 2003 Sep; 63(17):5381-9. PubMed ID: 14500372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma.
    Seftor RE; Seftor EA; Koshikawa N; Meltzer PS; Gardner LM; Bilban M; Stetler-Stevenson WG; Quaranta V; Hendrix MJ
    Cancer Res; 2001 Sep; 61(17):6322-7. PubMed ID: 11522618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma.
    Hendrix MJ; Seftor EA; Hess AR; Seftor RE
    Nat Rev Cancer; 2003 Jun; 3(6):411-21. PubMed ID: 12778131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
    Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ
    Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma.
    Clarijs R; Otte-Höller I; Ruiter DJ; de Waal RM
    Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):912-8. PubMed ID: 11923228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
    Hess AR; Seftor EA; Seftor RE; Hendrix MJ
    Cancer Res; 2003 Aug; 63(16):4757-62. PubMed ID: 12941789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vasculogenic mimicry--potential target for tumor therapy].
    Yue WY; Chen ZP
    Ai Zheng; 2006 Jul; 25(7):914-6. PubMed ID: 16831290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas.
    Sun B; Zhang S; Zhao X; Zhang W; Hao X
    Int J Oncol; 2004 Dec; 25(6):1609-14. PubMed ID: 15547697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry.
    Seftor RE; Seftor EA; Kirschmann DA; Hendrix MJ
    Mol Cancer Ther; 2002 Nov; 1(13):1173-9. PubMed ID: 12479698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
    Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.
    Sood AK; Fletcher MS; Coffin JE; Yang M; Seftor EA; Gruman LM; Gershenson DM; Hendrix MJ
    Am J Obstet Gynecol; 2004 Apr; 190(4):899-909. PubMed ID: 15118611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparanase, tissue factor, and cancer.
    Nadir Y; Vlodavsky I; Brenner B
    Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro.
    Lissitzky JC; Parriaux D; Ristorcelli E; Vérine A; Lombardo D; Verrando P
    Cancer Res; 2009 Feb; 69(3):802-9. PubMed ID: 19176384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination.
    Hendrix MJ; Seftor RE; Seftor EA; Gruman LM; Lee LM; Nickoloff BJ; Miele L; Sheriff DD; Schatteman GC
    Cancer Res; 2002 Feb; 62(3):665-8. PubMed ID: 11830517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal adhesion kinase promotes the aggressive melanoma phenotype.
    Hess AR; Postovit LM; Margaryan NV; Seftor EA; Schneider GB; Seftor RE; Nickoloff BJ; Hendrix MJ
    Cancer Res; 2005 Nov; 65(21):9851-60. PubMed ID: 16267008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner.
    Vartanian A; Stepanova E; Grigorieva I; Solomko E; Baryshnikov A; Lichinitser M
    Melanoma Res; 2011 Apr; 21(2):91-8. PubMed ID: 21389833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tissue factor pathway inhibitor in tumor growth and metastasis.
    Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL
    Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway.
    Liang X; Sun R; Zhao X; Zhang Y; Gu Q; Dong X; Zhang D; Sun J; Sun B
    J Cell Mol Med; 2017 Dec; 21(12):3579-3591. PubMed ID: 28699701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasculogenic mimicry: current status and future prospects.
    Zhang S; Zhang D; Sun B
    Cancer Lett; 2007 Sep; 254(2):157-64. PubMed ID: 17306454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.
    Maniotis AJ; Folberg R; Hess A; Seftor EA; Gardner LM; Pe'er J; Trent JM; Meltzer PS; Hendrix MJ
    Am J Pathol; 1999 Sep; 155(3):739-52. PubMed ID: 10487832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.